CFDA accepts WuXi-MedImmune’s IND for new mAb

By Zachary Brennan contact

- Last updated on GMT

CFDA accepts WuXi-MedImmune’s IND for new mAb

Related tags: Investigational new drug, Wuxi

The China Food and Drug Administration (CFDA) has accepted for review an Investigational New Drug (IND) application for WuXi and MedImmune's novel anti-IL6 monoclonal antibody (mAb) for rheumatoid arthritis. 

In September 2012, MedImmune, the biologics R&D arm of AstraZeneca, and WuXi formed the joint venture to develop and commercialize MEDI5117, a novel, investigational, long-acting mAb for autoimmune and inflammatory diseases. 

WuXi completed all CMC (chemistry, manufacturing and control), nonclinical, and clinical sections of the dossier, and the wholly owned subsidiary of the joint venture filed an IND for it with the Jiangsu provincial FDA as a Class 1 therapeutic biologic in December 2014.  WuXi's biologics and pre-clinical facilities in Shanghai, Suzhou, and Wuxi, China, passed the Jiangsu FDA's onsite inspections in January. 

The IND application has now been entered into the system of the CFDA for technical review. WuXi will continue to provide manufacturing for the program at its biologics facilities, as well as provide local regulatory, pre-clinical, and clinical trial support. 

Related topics: Clinical Development, Phase III-IV

Related news

Show more

Related products

show more

Because When It's On the Line... Capability Matters.

Because When It's On the Line... Capability Matters.

Baxter BioPharma Solutions | 01-Oct-2022 | Product Brochure

Baxter’s BioPharma Solutions business supports leading pharmaceutical companies in meeting their commercialization objectives by providing scientific expertise,...

ODM and CDASH in CRF design

ODM and CDASH in CRF design

Formedix | 15-Aug-2022 | Technical / White Paper

The lesser-known Operational Data Model (ODM) standard is often overlooked as it's not required by any regulators. So, why should you be interested...

Related suppliers

Follow us


View more